One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...

Black patients have similar immune checkpoint inhibitor (ICI) effectiveness and lower toxicities compared with White patients ...

The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

As expected with dual checkpoint inhibitor therapy, more immune-related adverse events were observed with ... Favezelimab (MK-4280) is an investigational anti-lymphocyte activation gene-3 (LAG-3) ...

Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025. Immutep Limited has released promising initial safety data ...

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s anti ...

Two of the newly discovered sequence variants with the largest effect on the risk of AITD are in a gene that codes for LAG-3 (Lymphocyte ... of immune checkpoint inhibitor therapy for cancer.